Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by Raymond James Financial Inc. from an “outperform” rating to a “market perform” rating in a research report issued on Tuesday.
Other research analysts have also recently issued research reports about the company. Cowen and Company reiterated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st. Zacks Investment Research raised Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 target price for the company in a report on Thursday, October 20th. Piper Jaffray Cos. reissued a “buy” rating and issued a $16.00 target price on shares of Nivalis Therapeutics in a report on Tuesday, August 30th. HC Wainwright reissued a “buy” rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Finally, Stifel Nicolaus lowered Nivalis Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $16.00 to $3.25 in a report on Tuesday. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $9.60.
Shares of Nivalis Therapeutics (NASDAQ:NVLS) traded down 54.24% on Tuesday, hitting $2.86. The stock had a trading volume of 1,818,249 shares. The stock has a 50 day moving average of $6.46 and a 200-day moving average of $5.84. Nivalis Therapeutics has a 12 month low of $2.78 and a 12 month high of $9.45. The stock’s market cap is $44.45 million.
Nivalis Therapeutics (NASDAQ:NVLS) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.11. Equities research analysts anticipate that Nivalis Therapeutics will post ($2.10) EPS for the current year.
In related news, EVP David Malcom Rodman sold 5,820 shares of Nivalis Therapeutics stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total value of $46,327.20. Following the completion of the sale, the executive vice president now owns 18,056 shares of the company’s stock, valued at $143,725.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.00% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock valued at $134,000 after buying an additional 1,189 shares in the last quarter. Spark Investment Management LLC bought a new stake in Nivalis Therapeutics during the third quarter valued at about $145,000. Paloma Partners Management Co bought a new stake in Nivalis Therapeutics during the second quarter valued at about $105,000. Endurant Capital Management LP raised its stake in Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock valued at $694,000 after buying an additional 19,629 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in Nivalis Therapeutics during the third quarter valued at about $1,664,000. 79.26% of the stock is owned by institutional investors.
Nivalis Therapeutics Company Profile